{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations","item":"https:\/\/www.regionalcancercare.org\/trials\/a-phase-3-randomized-trial-for-patients-with-de-novo-aml-comparing-standard-therapy-including-gemtuzumab-ozogamicin-go-to-cpx-351-with-go-and-the-addition-of-the-flt3-inhibitor-gilteritinib-for-pat\/#breadcrumbitem"}]}